TABLE 5.

The trends in the kidney and urine of highly correlated metabolites using PC analysis

Variable	PC Variables	PC Variance	ANOVA P	Post Hoc P
			All	STD versus HFD	HFD versus HFD+AICAR
Kidney
AA
LOX	15	64.2	0.02	0.03a	1
COX	15	45.0	0.81	1	1
P450	17	49.7	0.09	0.11	1
13 PGR	2	60.6	0.06	0.11	1
NE	3	42.2	0.20	0.34	1
EPA
LOX	3	93.0	0.00002	0.00008b	1
NE	2	77.9	0.0000003	0.000001b	1
DHA
LOX	4	77.2	0.007	0.006a	0.28
COX	2	96.0	0.001	0.001a	0.03
P450	2	97.5	0.003	0.003a	0.08
NE	4	95.8	0.008	0.007a	0.12
DGLA
LOX	2	92.5	0.03	0.06b	1
LA
LOX	2	98.0	0.07	0.40	1
NE	2	77.4	0.06	0.42	1
ALA
LOX	3	82.4	0.26	0.89	0.33
Urine
AA
LOX	28	46.3	0.06	0.42	0.95
COX	27	33.6	0.0005	0.004a	1
P450	19	53.9	0.12	0.70	1
13 PGR	3	47.7	0.03	0.04b	1
PGDH	5	45.6	0.00000002	0.00000001a	0.00003
NE	3	48.5	0.002	0.001a	0.09
EPA
LOX	3	96.8	0.14	0.214	0.33
COX	5	50.8	0.00022	0.000161b	0.03c
CYP	2	82.0	0.85	1	1
NE	3	82.2	0.05	0.24	0.06
DHA
LOX	6	55.0	0.49	0.94	1
COX	2	96.0	0.83	1	1
NE	4	71.3	0.85	1	1
DGLA
LOX	2	97.1	0.02	0.03a	1
LA
LOX	2	98.0	0.07	0.4	1
NE	2	77.4	0.04	0.36	0.72
ALA
LOX	3	82.4	0.26	0.88	0.33
Adrenic acid
COX	2	71.3	0.00002	0.00002b	0.006c

PC variables, number of eicosanoids in the PC; PC variance, amount of variance explained by the PC; ANOVA P, P generated comparing all three groups; HFD+AICAR, HFD and AICAR therapy; 13 PGR, delta13-15-ketoprostaglandin reductase; PGDH, 15-hydroxyprostaglandin dehydrogenase.

^aElevated with HFD.

^bDecreased with HFD.

^cElevated with AICAR